CoChat
Sign Up
Cited by 84

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Identification and characterization of two non-secreted PCSK9 mutants associated with familial hypercholesterolemia in cohorts from New Zealand and South Africa

Homer, Vivienne M., Marais, A. David, Charlton, Francesca, Laurie, Andrew D., Hurndell, Nicola, Scott, Russel, Mangili, Fabien, Sullivan, David R., Barter, Philip J., Rye, Kerry-Anne, George, Peter M., Lambert, Gilles·2008·Atherosclerosis
DOI 10.1016/j.atherosclerosis.2007.07.022
Open this paper in CoChat — free account

Abstract

We analysed the Proprotein Convertase Subtilisin Kexin type 9 (PCSK9) exons and intronic junctions of 71 patients with familial hypercholesterolemia (FH) in whom LDL receptor (LDLR) or apolipoprotein B100 mutations were excluded. The previously reported S127R and R237W mutations were found in South African families, whereas new missense mutations D129G and A168E were found in families from New Zealand. Only, the S127R and D129G mutations modify a highly conserved residue and segregate with the FH phenotype. We overexpressed those mutants in hepatoma cells and found that both S127R and D129G have reduced autocatalytic activity compared with wild-type PCSK9, whereas the A168E mutant is processed normally. The S127R and D129G mutants were not secreted from cells, unlike the A168E mutant and wild-type PCSK9. By immunoblot, we showed that the expression of the LDLR was reduced by 40% in cells overexpressing wild-type or A168E PCSK9 and further reduced by 30% when the S127R or D129G mutants were used. Paralleling the LDLR levels, LDL cellular binding decreased by 25% upon wild-type PCSK9 or A168E overexpression, and by 45% with both S127R and D129G mutants. Our study therefore indicates that PCSK9 mediated inhibition of the LDLR does not require PCSK9 autocatalytic cleavage or secretion, suggesting that PCSK9 may also function intracellularly.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.atherosclerosis.2007.07.022

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Show all 3 references

Research works printed but not linked: 34

  1. Tosi, 2007, Genetic defects causing familial hypercholesterolaemia: identification of deletions and duplications in the LDL-receptor gene and summary of all mutations found in patients attending the Hammersmith Hospital Lipid Clinic, Atherosclerosis, 194, 102, 10.1016/j.atherosclerosis.2006.10.003 · DOI
  2. Abifadel, 2003, Mutations in PCSK9 cause autosomal dominant hypercholesterolemia, Nat Genet, 34, 154, 10.1038/ng1161 · DOI · Paper page
  3. Allard, 2005, Novel mutations of the PCSK9 gene cause variable phenotype of autosomal dominant hypercholesterolemia, Hum Mutat, 26, 497, 10.1002/humu.9383 · DOI
  4. Leren, 2004, Mutations in the PCSK9 gene in Norwegian subjects with autosomal dominant hypercholesterolemia, Clin Genet, 65, 419, 10.1111/j.0009-9163.2004.0238.x · DOI
  5. Pisciotta, 2006, Additive effect of mutations in LDLR and PCSK9 genes on the phenotype of familial hypercholesterolemia, Atherosclerosis, 186, 433, 10.1016/j.atherosclerosis.2005.08.015 · DOI
  6. Timms, 2004, A mutation in PCSK9 causing autosomal-dominant hypercholesterolemia in a Utah pedigree, Hum Genet, 114, 349, 10.1007/s00439-003-1071-9 · DOI
  7. Berge, 2006, Missense mutations in the PCSK9 gene are associated with hypocholesterolemia and possibly increased response to statin therapy, Arterioscler Thromb Vasc Biol, 26, 1094, 10.1161/01.ATV.0000204337.81286.1c · DOI · Paper page
  8. Hooper, 2007, The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population, Atherosclerosis, 193, 445, 10.1016/j.atherosclerosis.2006.08.039 · DOI
  9. Kotowski, 2006, A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol, Am J Hum Genet, 78, 410, 10.1086/500615 · DOI · Paper page
  10. Zhao, 2006, Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote, Am J Hum Genet, 79, 514, 10.1086/507488 · DOI
  11. Benjannet, 2004, NARC-1/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (ldl) receptor and ldl cholesterol, J Biol Chem, 279, 48865, 10.1074/jbc.M409699200 · DOI · Paper page
  12. Lambert, 2006, Fasting induces hyperlipidemia in mice overexpressing proprotein convertase subtilisin kexin type 9: lack of modulation of very-low-density lipoprotein hepatic output by the low-density lipoprotein receptor, Endocrinology, 147, 4985, 10.1210/en.2006-0098 · DOI
  13. Maxwell, 2004, Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype, Proc Natl Acad Sci USA, 101, 7100, 10.1073/pnas.0402133101 · DOI · Paper page
  14. Park, 2004, Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver, J Biol Chem, 279, 50630, 10.1074/jbc.M410077200 · DOI · Paper page
  15. Rashid, 2005, Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9, Proc Natl Acad Sci USA, 102, 5374, 10.1073/pnas.0501652102 · DOI · Paper page
  16. Maxwell, 2005, Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment, Proc Natl Acad Sci USA, 102, 2069, 10.1073/pnas.0409736102 · DOI · Paper page
  17. Cameron, 2006, Effect of mutations in the PCSK9 gene on the cell surface LDL receptors, Hum Mol Genet, 15, 1551, 10.1093/hmg/ddl077 · DOI · Paper page
  18. Lagace, 2006, Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice, J Clin Invest, 116, 2995, 10.1172/JCI29383 · DOI · Paper page
  19. Zhang, 2007, Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat a of low density lipoprotein receptor decreases receptor recycling and increases degradation, J Biol Chem, 282, 18602, 10.1074/jbc.M702027200 · DOI · Paper page
  20. Cunningham, 2007, Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia, Nat Struct Mol Biol, 14, 413, 10.1038/nsmb1235 · DOI · Paper page
  21. Benjannet, 2006, The proprotein convertase (PC) PCSK9 is inactivated by furin and/or PC5/6A: functional consequences of natural mutations and post-translational modifications, J Biol Chem, 281, 30561, 10.1074/jbc.M606495200 · DOI · Paper page
  22. Naureckiene, 2003, Functional characterization of Narc 1, a novel proteinase related to proteinase K, Arch Biochem Biophys, 420, 55, 10.1016/j.abb.2003.09.011 · DOI
  23. Seidah, 2003, The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation, Proc Natl Acad Sci USA, 100, 928, 10.1073/pnas.0335507100 · DOI · Paper page
  24. Horton, 2007, Molecular biology of PCSK9: its role in LDL metabolism, Trends Biochem Sci, 32, 71, 10.1016/j.tibs.2006.12.008 · DOI · Paper page
  25. Lambert, 2006, PCSK9: a promising therapeutic target for dyslipidemias?, Trends Endocrinol Metab, 17, 79, 10.1016/j.tem.2006.02.001 · DOI
  26. Lambert, 2007, Unravelling the functional significance of PCSK9, Curr Opin Lipidol, 18, 304, 10.1097/MOL.0b013e3281338531 · DOI
  27. Laurie, 2004, Genetic screening of patients with familial hypercholesterolaemia (FH): a New Zealand perspective, Atheroscler Suppl, 5, 13, 10.1016/j.atherosclerosissup.2004.09.001 · DOI
  28. Haddad, 1997, Development of a microsatellite-based approach to co-segregation analysis of familial hypercholesterolaemic kindreds, Ann Hum Genet, 61, 497, 10.1017/S0003480097006532 · DOI
  29. Sun, 2005, Evidence for effect of mutant PCSK9 on apolipoprotein B secretion as the cause of unusually severe dominant hypercholesterolaemia, Hum Mol Genet, 14, 1161, 10.1093/hmg/ddi128 · DOI
  30. Humphries, 2006, Genetic causes of familial hypercholesterolaemia in patients in the UK: relation to plasma lipid levels and coronary heart disease risk, J Med Genet, 43, 943, 10.1136/jmg.2006.038356 · DOI · Paper page
  31. Holla, 2007, Degradation of the LDL receptors by PCSK9 is not mediated by a secreted protein acted upon by PCSK9 extracellularly, BMC Cell Biol, 8, 9, 10.1186/1471-2121-8-9 · DOI
  32. McNutt, 2007, Catalytic activity is not required for secreted PCSK9 to reduce LDL receptors in HepG2 cells, J Biol Chem, 282, 20799, 10.1074/jbc.C700095200 · DOI · Paper page
  33. Fisher, 2007, PCSK9-dependent LDL receptor regulation: effects of pH and LDL, J Biol Chem, 282, 20502, 10.1074/jbc.M701634200 · DOI · Paper page
  34. Graham, 2007, Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice, J Lipid Res, 48, 763, 10.1194/jlr.C600025-JLR200 · DOI

Cited by

Sorted by citations

See all 84

Metadata

Authors
Homer, V. M., Marais, A. D., Charlton, F., Laurie, A. D., Hurndell, N., Scott, R., Mangili, F., Sullivan, D. R., Barter, P. J., Rye, K.-A., George, P. M., & Lambert, G.
Venue
Atherosclerosis
Publisher
Elsevier BV
Published
2008-02
Volume
196
Issue
2
Pages
659-666
ISSN
0021-9150
DOI
10.1016/j.atherosclerosis.2007.07.022
Cited by
84
References
3
Language
en
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review